论文部分内容阅读
目的探讨羟苯磺酸钙胶囊联合盐酸贝那普利治疗糖尿病肾病患者的临床疗效。方法选取2012年2月至2014年2月沈阳市第一人民医院收治的糖尿病肾病患者资料90例,按随机数字表法将患者分为对照组和观察组,各45例。对照组患者服用盐酸贝那普利进行治疗,观察组患者在对照组基础上口服羟苯磺酸钙胶囊。比较两组患者的血肌酐、尿素氮、24 h尿白蛋白、24 h尿白蛋白排泄率以及不良反应发生情况。结果治疗后12周,观察组患者的24 h尿白蛋白、24 h尿白蛋白排泄率均明显低于对照组,差异均有统计学意义(均P<0.05);两组患者均未出现肝功能损伤、恶心呕吐等严重药物不良反应。结论羟苯磺酸钙胶囊联合盐酸贝那普利治疗糖尿病肾病临床疗效明显,可明显减少尿白蛋白,且不良反应较少。
Objective To investigate the clinical efficacy of calcium dobesilate combined with benazepril hydrochloride in patients with diabetic nephropathy. Methods Ninety patients with diabetic nephropathy who were admitted to Shenyang First People’s Hospital from February 2012 to February 2014 were selected and divided into control group and observation group according to random number table. Patients in the control group were treated with benazepril hydrochloride, and those in the observation group were orally administered calcium dobesilate on the basis of the control group. Serum creatinine, urea nitrogen, 24 h urinary albumin, 24 h urinary albumin excretion rate and adverse reactions were compared between the two groups. Results The urinary albumin excretion rate at 24 h and 24 h after operation in the observation group were significantly lower than those in the control group at 12 weeks after treatment (all P <0.05). No hepatic Functional impairment, nausea, vomiting and other serious adverse drug reactions. Conclusion Calcium dobesilate capsules combined with benazepril hydrochloride in the treatment of diabetic nephropathy have obvious curative effect, can significantly reduce urinary albumin, and less adverse reactions.